Category: GeoVax Recent News

Quarter Highlighted by GEO-MVA Acceleration Amid Global Mpox Emergency, Gedeptin® Expansion into New Solid Tumor Programs, and Strong GEO-CM04S1 Clinical Data in Immunocompromised Patients  Company to Host Conference Call Today at 4:30 p.m. ET ATLANTA, GA, November 13, 2025 – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing multi-antigenic vaccines and immunotherapies against infectious…

Positioning GeoVax as a Diversified, Made-in-America Vaccine Leader with Global Market Relevance Atlanta, GA – November 10, 2025 – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing multi-antigen vaccines and immunotherapies for infectious diseases and cancer, today recognized World Immunization Day, a global observance highlighting the lifesaving power of vaccines and the urgent need…

Atlanta, GA – November 4, 2025 – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing multi-antigen vaccines and immunotherapies for infectious diseases and cancer, today announced that it will report its financial results for the quarter ended September 30, 2025, after the close of U.S. markets on Thursday, November 13, 2025. Following the release,…

Relocations Strengthen Ties to Georgia’s Bio-Ecosystem and Position GeoVax for Late-Stage Development and Market Readiness Atlanta, GA – November 3, 2025 – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and multi-antigen vaccines against cancers and infectious diseases, today announced relocations of its corporate headquarters and laboratory operations to new facilities in the…

Following John Crowley’s Testimony, GeoVax Highlights Urgent Need for Vaccine Platform Diversity, Onshoring Manufacturing, and Protecting Immunocompromised Populations Atlanta, GA — October 30, 2025 — GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing multi-antigen vaccines and immunotherapies for infectious diseases and cancer, today responded to testimony delivered at a Senate HELP Committee hearing by…

GEO-CM04S1 Designed to Deliver Broader, More Durable Protection for the 40 Million Americans Left Vulnerable by Limited Effectiveness of Current Vaccines Atlanta, GA — October 28, 2025 — GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing multi-antigen vaccines and immunotherapies for infectious diseases and cancer, today highlighted the recently issued Infectious Diseases Society of…

EMA Endorses Expedited Development Pathway for GEO-MVA; Company Advances U.S.-Based Continuous Cell Line Manufacturing to Address Fragile Supply Chains and Align with Federal Pandemic Preparedness Initiatives ATLANTA, GA – October 20, 2025 – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing multi-antigen vaccines and immunotherapies for infectious diseases and cancer, today emphasized the urgent…

Presentations Underscore Favorable Safety Profile and Robust T-Cell Responses of GEO-CM04S1 in Vulnerable Populations ATLANTA, GA – October 16, 2025 – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing multi-antigen vaccines and immunotherapies for infectious diseases and cancer, today announced presentations by its senior scientific leadership at the World Vaccine Congress Europe 2025, held…

Executives to Participate at World Vaccine Congress Europe (Amsterdam, Oct 13–16) and BIO-Europe Fall (Vienna, Nov 3–5), and Meet With NGOs, Industry Partners and Academic Collaborators ATLANTA, GA – October 13, 2025 – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing multi-antigen vaccines and immunotherapies for infectious diseases and cancer, today announced that senior leadership…

Presentations to Highlight Interim Safety Data and Special-Populations Insights for GEO-CM04S1 in Immunocompromised Patients ATLANTA, GA – October 9, 2025 – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing multi-antigen vaccines and immunotherapies for infectious diseases and cancer, today announced that members of its executive medical and scientific team will deliver presentations at the upcoming World…

David Dodd, Chairman & CEO, Available for Investor Meetings   ATLANTA, GA, October 7, 2025 – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing multi-antigen vaccines and immunotherapies for infectious diseases and cancer, today announced that its Chairman and CEO, David Dodd, will participate in the 4th Annual ROTH Healthcare Opportunities Conference, taking place…

ATLANTA, GA, September 30, 2025 – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancer and infectious diseases, today announced that it has entered into a securities purchase agreement with certain healthcare-focused institutional investors for the purchase and sale of 3,968,256 shares of its common stock (or common stock equivalents…